NIMH IRP Translational Neuropsychopharmacology Initiative
The National Institute of Mental Health (NIMH) has become increasingly aware of the reduced investment by pharmaceutical companies in the development of therapeutics for treating psychiatric disorders despite the unmet medical need. Consequently, the NIMH Intramural Research Program (IRP) is proposing to re-invigorate psychiatric drug discovery by facilitating and de-risking the discovery and development of novel treatments. Support for the discovery and development of new treatments for psychiatric disorders including target validation, biomarker development, IND enabling studies, and Phase I safety / tolerability and Phase II proof of concept studies are all in scope for this important NIMH IRP initiative.
To steer this initiative the NIMH IRP has established the NIMH Translational Neuropsychopharmacology Task Force (TNTF). The TNTF is comprised of a panel of experts from the pharmaceutical industry and the NIH who will critically review, prioritize and recommend new proposals for support by the NIMH IRP.
Janet Clark, Ph.D.
Director, Translational Neuropsychopharmacology Initiative
Members of the NIMH IRP Translational Neuropsychopharmacology Task Force
NIMH IRP Translational Neuropsychopharmacology Task Force members include: Janet Clark, PhD of NIMH IRP; Alan Cross, PhD, of Astrazeneca; Peter Hutson, PhD, of Teva Pharmaceuticals; Kenneth Maynard, PhD, FAHA, of Takeda Pharmaceuticals; Paul McGonigle, PhD, of Drexel University College of Medicine; Jeris Minor of Jeris, LLC; Philip Sanderson, PhD, of NCATS; Mark Smith, MD, of VistaGen Therapeutics; and Lois Winsky, PhD, of NIMH.
Interested in submitting a proposal to the NIMH IRP TNTF?
Contact Janet Clark by email or phone at: Janet.Clark@nih.gov or 301-402-2773